<%@ Page Title="" Language="C#" MasterPageFile="~/masterpages/module.master" AutoEventWireup="true" CodeFile="references-nl.aspx.cs" Inherits="secure_modules_module3_references_nl" %>

<asp:Content ID="Content1" ContentPlaceHolderID="contentBreadcrumb" Runat="Server">
     Diagnose en Assessment \ Alle referenties
</asp:Content>
<asp:Content ID="Content2" ContentPlaceHolderID="contentSideBar" Runat="Server">
</asp:Content>
<asp:Content ID="Content3" ContentPlaceHolderID="contentMain" Runat="Server">
    <div class="module3page">
        <h1>
            Alle referenties</h1>
            <div class="icon_reading">
        <ul class="references">
            <li><span>Edwards RG, Barlow JH, Turner AP. Experiences of diagnosis and treatment among
                people with multiple sclerosis. <em>J Eval Clin Pract </em>2008; 14(3): 460−4.</span></li>
            <li><span>Poser CM, Paty DW, Scheinberg L, <em>et al</em>. New diagnostic criteria for
                multiple sclerosis: Guidelines for research protocols. <em>Ann Neurol </em>1983;
                13(3): 227−31.</span></li>
            <li><span>McDonald WI, Compston A, Edan G, <em>et al</em>. Recommended diagnostic criteria
                for multiple sclerosis: guidelines from the International Panel on the diagnosis
                of multiple sclerosis. <em>Ann Neurol</em> 2001; 50(1): 121–7.</span></li>
            <li><span>Polman CH, Reingold SC, Edan G,<em> et al</em>. Diagnostic criteria for multiple
                sclerosis: 2005 revisions to the “McDonald Criteria”. <em>Ann Neurol</em> 2005;
                58(6): 840−6.</span></li>
            <li><span>Polman CH, Reingold SC, Banwell B, <em>et al</em>. Diagnostic criteria for
                multiple sclerosis: 2010 revisions to the “McDonald Criteria”. <em>Ann Neurol</em>
                2011; 69(2): 292−302.</span></li>
            <li><span>Martin J, Lowenstein DH, Hauser SL in Harrison’s Neurology in Clinical Medicine.
                Ed Hauser SL. Hill Companies, Inc. 2006; p17−23.</span></li>
            <li><span>Schumacher G, Beebe G, Kibler R, <em>et al</em>. Problems of experimental
                trials of therapy in multiple sclerosis: Report by the panel on the evaluation of
                experimental trials of therapy in multiple sclerosis. <em>Ann N Y Acad Sci </em>
                1965; 122: 552–68.</span></li>
            <li><span>Wingerchuk DM, Lennon VA, Pittock SJ, <em>et al</em>. Revised diagnostic criteria
                for neuromyelitis optica.<em> Neurology</em> 2006; 66(10): 1485−9.</span></li>
            <li><span>Miller D, Weinshenker B, Fillipi M, <em>et al</em>. Differential diagnosis
                of suspected multiple sclerosis: a consensus approach. <em>Mult Scler </em>2008;
                14(9): 1157–74.</span></li>
            <li><span>Marrie RA, Horwitz R, Cutter G, <em>et al</em>. Comorbidity delays diagnosis
                and increases disability at diagnosis in MS. <em>Neurology</em> 2009; 72(2): 117−24.</span></li>
            <li><span>Fisniku LK, Brex PA, Altmann DR, <em>et al</em>. Disability and T2 MRI lesions:
                a 20-year follow-up of patients with relapse onset of multiple sclerosis. <em>Brain
                </em>2008; 131(Pt 3): 808−17.</span></li>
            <li><span>Okuda DT, Mowry EM, Beheshtian A,<em> et al</em>. Incidental MRI anomalies
                suggestive of multiple sclerosis: the radiologically isolated syndrome.<em> Neurology</em>
                2009; 72(9): 800–5.</span></li>
            <li><span>Lebrun C, Bensa C, Debouverie M, <em>et al</em>. Association between clinical
                conversion to multiple sclerosis in radiologically isolated syndrome and magnetic
                resonance imaging, cerebrospinal fluid, and visual evoked potential: follow up of
                70 patients. <em>Arch Neurol </em>2009; 66(7): 841–6.</span></li>
            <li><span>Siva S, Saip S, Altintas A, et al. Multiple sclerosis risk in radiologically
                uncovered asymptomatic possible inflammatory demyelinating disease.<em> Mult Scler</em>
                2009; 15(8): 918–27.</span></li>
            <li><span>Okuda DT, Mowry EM, Cree BA, <em>et al</em>. Asymptomatic spinalcord lesions
                predict disease progression in radiologically isolated syndrome. <em>Neurology</em>
                2011; 76(8): 686–92.</span></li>
            <li><span>Barkhof F, Filippi M, Miller DH, <em>et al</em>. Comparison of MR imaging
                criteria at first presentation to predict conversion to clinically definite multiple
                sclerosis. <em>Brain</em> 1997; 120(Pt 11): 2059–69.</span></li>
            <li><span>Tintoré M, Rovira A, Martínez MJ,<em> et al</em>. Isolated demyelinating syndromes:
                comparison of different MR imaging criteria to predict conversion to clinically
                definite multiple sclerosis. AJNR <em>Am J Neuroradiol</em> 2000; 21(4): 702–6.</span></li>
            <li><span>McHugh JC, Galvin PL, Murphy RP. Retrospective comparison of the original
                and revised McDonald Criteria in a general neurology practice in Ireland. <em>Mult Scler</em>
                2008; 14(1): 81–5.</span></li>
            <li><span>Albertyn C, O’Dowd S, McHugh J, <em>et al</em>. Compliance with McDonald criteria
                and red flag recognition in a general neurology practice in Ireland. <em>Mult Scler</em>
                2010; 16(6): 678–84.</span></li>
            <li><span>Swanton JK, Fernando K, Dalton CM, <em>et al</em>. Modification of MRI criteria
                for multiple sclerosis in patients with clinically isolated syndromes. <em>J Neurol
                    Neurosurg Psychiatry</em> 2006; 77(7): 830–3.</span></li>
            <li><span>Swanton JK, Rovira A, Tintore M, <em>et al</em>. MRI criteria for multiple
                sclerosis in patients presenting with clinically isolated syndromes: a multicentre
                retrospective study. <em>Lancet Neurol</em> 2007; 6(8): 677–86.</span></li>
            <li><span>Montalban X, Tintoré M, Swanton J, <em>et al</em>. MRI criteria for MS in
                patients with clinically isolated syndromes.<em> Neurology </em>2010; 74(5): 427–34.</span></li>
            <li><span>Tur C, Tintoré M, Rovira A, <em>et al</em>. Very early scans for demonstrating
                dissemination in time in multiple sclerosis. <em>Mult Scler</em> 2008; 14(5): 631–5.</span></li>
            <li><span>Rovira A, Swanton J, Tintoré M, <em>et al</em>. A single, early magnetic resonance
                imaging study in the diagnosis of multiple sclerosis. <em>Arch Neurol </em>2009;
                66(5): 587−92.</span></li>
            <li><span>Boesch C. Molecular aspects of magnetic resonance imaging and spectroscopy.
                <em>Mol Aspects Med</em> 1999; 20(4−5): 185−318.</span></li>
            <li><span>Wattjes MP, Harzheim M, Lutterbey GG, <em>et al</em>. Does high field MRI
                allow an earlier diagnosis of multiple sclerosis?<em> J Neurol</em> 2008; 255(8):
                1159−63.</span></li>
            <li><span>Fauci AS, Braunwald E, Kasper DL <em>et al</em>. Multiple sclerosis and other
                demyelinating diseases. Chapter 375 in: <em>Harrison’s Principles of Internal Medicine</em>.
                17th ed. New York, NY: McGraw-Hill; 2008.</span></li>
            <li><span>Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in
                multiple sclerosis. <em>J Neuroimaging</em> 2005; 15(4 Suppl): 10S−21S.</span></li>
            <li><span>Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited.
                <em>Curr Opin Neurol</em> 2002; 15(3): 239−45. </span></li>
            <li><span>Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid:
                an update on methodology and clinical usefulness. <em>J Neuroimmunol</em> 2006;
                180(1): 17–28.</span></li>
            <li><span>Compston A, Confavreux C, Lassmann H <em>et al</em>. McAlpine’s Multiple Sclerosis.
                4th ed. London: Churchill Livingstone; 2006.</span></li>
            <li><span>Mehling M, Kuhle J, Regeniter A. 10 most commonly asked questions about cerebrospinal
                fluid characteristics in demyelinating disorders of the central nervous system.
                <em>Neurologist</em> 2008; 14(1): 60–5.</span></li>
            <li><span>Bourahoui A, de Seze J, Guttierez R, <em>et al</em>. CSF isoelectrofocusing
                in a large cohort of MS and other neurological diseases. <em>Eur J Neurol </em>2004;
                11(8): 525–9.</span></li>
            <li><span>Zaffaroni M. Cerebrospinal fluid findings in Devic’s neuromyelitis optica.
                <em>Neurol Sci</em> 2004; 25(Suppl 4): S368–70.</span></li>
            <li><span>Tintoré M, Rovira A, Río J, <em>et al</em>. Do oligoclonal bands add information
                to MRI in first attacks of multiple sclerosis? <em>Neurology </em>2008; 70(13 Pt
                2): 1079−83.</span></li>
            <li><span>Hassan-Smith G and Douglas MR. Epidemiology and diagnosis of multiple sclerosis.
                <em>Br J Hosp Med (Lond)</em> 2011; 72(10): M146−53.</span></li>
            <li><span>Chiappa K. Pattern-shift visual, brainstem auditory and short-latency somatosensory
                evoked potentials in multiple sclerosis. <em>Ann N Y Acad Sci</em> 1984; 436: 315–27.</span></li>
            <li><span>Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials
                in identifying clinically silent lesions in patients with suspected multiple sclerosis
                (an evidence-based review). <em>Neurology</em> 2000; 54(9): 1720–5.</span></li>
            <li><span>Pelayo R, Montalban X, Minoves T, <em>et al</em>. Do multimodal evoked potentials
                add information to MRI in clinically isolated syndromes? <em>Mult Scler </em>2010;
                16(1): 55−61.</span></li>
            <li><span>Giesser BS. Diagnosis of multiple sclerosis. <em>Neurol Clin</em> 2011; 29(2):
                381−8.</span></li>
            <li><span>Graber JJ and Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis.
                <em>J Neurol Sci </em>2011; 305(1−2): 1−10.</span></li>
            <li><span>Multiple Sclerosis Society; Frohman E M, in A Practical Primer: Multiple Sclerosis
                for the Physician Assistant Ed; Frohman T, O’Donoghue D, and Northrop D. 2011: 71−81.</span></li>
            <li><span>Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded
                disability status scale (EDSS). <em>Neurology</em> 1983; 33(11): 1444−52.</span></li>
            <li><span>Kurtzke JF. Historical and clinical perspectives of the expanded disability
                status scale. <em>Neuroepidemiology</em> 2008; 31(1): 1−9.</span></li>
            <li><span>Rudick RA, Polman CH, Cohen JA,<em> et al</em>. Assessing disability progression
                with the Multiple Sclerosis Functional Composite.<em> Mult Scler</em> 2009; 15(8):
                984−97.</span></li>
            <li><span>Rudick R, Antel J, Confavreux C, <em>et al</em>. Recommendations from the
                National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. <em>Ann
                    Neurol</em> 1997; 42(3): 379−82.</span></li>
            <li><span>Fischer JS, Jack AJ, Knicker JE, Rudick RA, Cutter G. <em>Administration and
                scoring manual for the Multiple Sclerosis Functional Composite Measure (MSFC)</em>.
                Canada: Demos, 1999.</span></li>
            <li><span>Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple
                sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg
                tests. <em>Arch Phys Med Rehabil</em> 1988; 69(10): 850−4.</span></li>
            <li><span>Gronwall DM. Paced auditory serial-addition task: a measure of recovery from
                concussion. <em>Percept Mot Skills</em> 1977; 44(2): 367−73.</span></li>
            <li><span>Cutter GR, Baier ML, Rudick RA, <em>et al</em>. Development of a multiple
                sclerosis functional composite as a clinical trial outcome measure.<em> Brain</em>
                1999; 122(Pt 5): 871−82.</span></li>
            <li><span>Kalkers NF, Bergers L, de Groot V,<em> et al</em>. Concurrent validity of
                the MS Functional Composite using MRI as a biological disease marker. <em>Neurology
                </em>2001; 56(2): 215−19.</span></li>
            <li><span>Kalkers NF, Bergers E, Castelijns JA, <em>et al</em>. Optimizing the association
                between disability and biological markers in MS. <em>Neurology </em>2001; 57(7):
                1253−8.</span></li>
            <li><span>Fisher E, Rudick RA, Cutter G, <em>et al</em>. Relationship between brain
                atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
                <em>Mult Scler </em>2000; 6(6): 373−7.</span></li>
            <li><span>Roxburgh RH, Seaman SR, Masterman T, <em>et al</em>. Multiple Sclerosis Severity
                Score: using disability and disease duration to rate disease severity. <em>Neurology
                </em>2005; 64(7); 1144−51.</span></li>
        </ul>
        </div>
    </div>
</asp:Content>

